Alzheimer Disease Clinical Trials in Las Vegas, Nevada

5 studies are recruiting for alzheimer disease in Las Vegas, Nevada right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

   The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who c…

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Redbird Research, Las Vegas, Nevada

   Locations

   252 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06937229 on ClinicalTrials.gov

2. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

   The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Redbird Research, Las Vegas, Nevada

   Locations

   162 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07011732 on ClinicalTrials.gov

3. Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

   This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

   Stage

   Phase 2

   Ages

   55 to 90

   Site

   Local Institution - 0041, Las Vegas, Nevada

   Locations

   78 in total

   Run by

   Celgene

   See if you can join NCT06808984 on ClinicalTrials.gov

4. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

   The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

   Stage

   Phase 3

   Ages

   55 and older

   Site

   Vector Clinical Trials, Las Vegas, Nevada

   Locations

   59 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07602582 on ClinicalTrials.gov

5. Trial-Ready Cohort-Down Syndrome (TRC-DS)

   The purpose of the Trial-Ready Cohort - Down Syndrome (TRC-DS) is to enroll 120 healthy adults with Down syndrome (DS), between the ages of 25-55, into a trial ready cohort (TRC), and up to 550 participants in total including co-enrolled in the Alzheimer Biomarkers Consortium - Down Syndrome (ABC-D…

   Stage

   Not phased

   Ages

   25 to 55

   Site

   Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, Las Vegas, Nevada

   Locations

   22 in total

   Run by

   University of Southern California

   See if you can join NCT04165109 on ClinicalTrials.gov